Clozapine and risperidone in secondary progressive MS (CRISP)
Type of Study/Intervention
Form of MS
Secondary progressive MS
Clozapine and risperidone are medicines that are currently used to treat mental health disorders. These medicines have been shown to have anti-inflammatory effects in the brain and therefore may also be useful for treating multiple sclerosis (MS). At the dose used in patients with mental illnesses clozapine and risperidone can have a range of side effects, but research has shown that a lower dose may be suitable for treating MS.
The main purpose of this study is to assess the safety and acceptability of treatment with a low dose of clozapine or risperidone in patients with secondary progressive MS by comparing their use to people given a placebo (inactive medicine). The study will also look at whether these medicines can reduce the symptoms of MS, and how they might affect the immune system. This information will help determine if one or both of these medicines should be further developed as a treatment for MS.
- Have secondary progressive multiple sclerosis
- Are aged 18 – 55 years
- Have an expanded disability status score of 3.5 to 6.5
- Relapsing-remitting MS
- Pregnant or lactating women
- Patients unable to undergo regular blood tests or MRI scans
- Patients with contraindications to clozapine or risperidone
- Known hypersensitivity to clozapine, risperidone or to any of the excipients thereof
- Reported past intolerance to clozapine or risperidon
A range of other exclusion criteria also apply including certain medical conditions and/or the use of certain medications that may interact with, or interfere, with the action of clozapine or risperidone. For full details visit the Australian New Zealand Clinical Trials Registry here.
Anticipated start date
6 May 2016
Research Nurse, Wellington Regional Hospital, Wellington New Zealand
Email: [email protected]
Phone: +64 (04) 806-0078
Full details of the trial can be found on the ANZCTR clinical trials database.